Zhengye Biotechnology Holding Limited · NASDAQ:ZYBT
Zhengye Biotechnology — IPO Roadshow (August 2024)
30 slides from Zhengye Biotechnology's IPO roadshow presentation, Aug 27, 2024
Slide 1: Zhengye Biotechnology Holding Limited Investor Presentation
Issuer Free Writing Prospectus dated August 27, 2024 Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Relating to Preliminary Prospectus dated August 22, 2024 Registration Statement No. 333 - 276436 Zhengye Biotechnology Holding Limited Proposed Nasdaq Ticker: ZYBT Investor Prese
Slide 2: Free Writing Prospectus Statement
Free Writing Prospectus Statement This free writing prospectus relates to the proposed public offering of ordinary shares (“Ordinary Shares”) of Zhengye Biotechnology Holding Limited (“we”, “us”, or “our”) and should be read together with the Registration Statement we filed with the U . S . Securiti
Slide 3: Forward-Looking Statement
Forward - Looking Statement 3 This presentation contains forward - looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties . Forward - looking statements give our current expectations or forecasts of future events . You
Slide 4: Offering Summary
Offering Summary Zhengye Biotechnology Holding Limited Issuer Nasdaq Capital Market: ZYBT Exchange/Ticker Ordinary Shares Securities Offered 45,666,376 Ordinary Shares Pre - Offering Shares Outstanding 1,500,000 Ordinary Shares (or 1,725,000 Ordinary Shares if the Underwriter exercises its over - al
Slide 5: Investment Highlights
Investment Highlights 1 2 3 4 5 High Production Quality and Quality Control 44 Diversified Products Extensive Distribution Channels Strong Research and Development Capabilities Experienced Management Team 5 See offering documents for further risks and disclosures. There is no guarantee that any spec
Slide 6: Content
C o ntent Company and Business Overview 01 Industry Overview Growth Strategies Financial Highlights 02 03 04
Slide 7: Company Overview
Company Overview We focus on the research , development , manufacturing, and sales of veterinary vaccines , with an emphasis on vaccines for livestock. We market a diverse range of vaccines , including vaccines for swine , cattle , goats , sheep , poultry , and dogs . Source: * Company Websites, Com
Slide 8: Company Overview
1 quality examination center 3 GMP veterinary vaccine production floors 1 independent R&D center 13 GMP vaccine production lines Company Overview Our mission is to become a world - leading manufacturer and distributor of veterinary vaccines 8 See offering documents for further risks and disclosures.
Slide 9: The Production Process
The Production Process • Sales department receives orders • Purchasing department purchase raw materials and components • Manufacturing is conducted under the supervision of the quality control team • Product Quality Control • Lot release of vaccines by component authorities • Customer Delivery 9 Se
Slide 10: Corporate Structure
Corporate Structure T L j i n m ao Limited (BVI) Visuccess Holding Limited (Hong Kong) Zhengye Biotechnology Holding Limited (Cayman) VVAX Skyline Holdings Limited (BVI) Peg Biotechnology (HK) Holding Limited (Hong Kong) Hainan Senhan Biotechnology Co., Ltd. (PRC) Jilin Zhengye Biological Products C
Slide 11: Strong R&D Capabilities – Independent R&D
Strong R&D Capabilities – Independent R&D • Have 49 experienced experts (+10 years experience) work for our R&D department with glory achievements and awards. • Own 1 research center, which collectively has helped the operating entity develop dozens of vaccines, inventions, and utility models. • Dev
Slide 12: Strong R&D Capabilities - Cooperative R&D
Strong R&D Capabilities - Cooperative R&D • Maintained long - term cooperative relationships with universities and institutions: - Universities and research institutes - early - stage basic research - Our R&D - basic research , pilot study and industrialization research 12 • Licensed to use vaccine
Slide 13: New Product Development Process
New Product Development Process Lab investigation Pilot Production Clinical Trial Appli c a tion Clinical Trial Application for Registration of New Veterinary Drugs Conformity Certification of New Inspection Veterinary Drugs Serial No. Assignment Commercialization Steps highlighted in yellow are sub
Slide 14: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products 18 Swine vaccine 5 Bovine and Ovine vaccine 1 Pet vaccine 20 Poultry vaccine 14 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and ther
Slide 15: Diversified Products – Commercialized Products
Diversified Products – Commercialized Products 15 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss
Slide 16: Diversified Products – Products in Pipeline
Diversified Products – Products in Pipeline 16 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss Collaborator Clinical Trial Status Status T y pe o f Vaccine
Slide 17: High Production Quality - By GMP & ISO
High Production Quality - By GMP & ISO Raw Materials and Viral Seeds Inspection Work in Process Check Product Examination The Whole Process of Manufacturing Quality Control Management System Examinations Physical property inspection • the appearance • properties • dosage form • color • other aspects
Slide 18: Extensive Distribution Channels
7 5 .4% 2 3 .4% 1.2% Extensive Distribution Channels • Domestic distributors cover 29 provincial - level administrative regions of China • International distributors cover Vietnam, Pakistan, and Egypt • 212* distributors globally 18 Direct Sales Channel – 75.4% * • Participating tender and procureme
Slide 19: Experienced Management Team and Employees
Experienced Management Team and Employees 19 Songlin Song Chief Executive Officer Veterinarian Professionals with more than 20 years of industry experience • Chief Executive Officer since May 2023 . • Director and General Manager of our operating entity since September 2018 . • General Manager of Ch
Slide 20: Experienced Management Team
Experienced Management Team 20 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss Yuyou He Vice General Manager Veterinarian Professionals with more than 40 y
Slide 21: Content
C o ntent Company and Business Overview 01 Industry Overview Growth Strategies Financial Highlights 02 03 04
Slide 22: Industry Overview
Industry Overview 1.6 2 .2 2 .5 2 .5 2 .7 2 .9 3 .0 3 .2 2 0 2 6E Ranking of Revenue of China’s Veterinary Vaccine Companies (2) RMB Billion, 2022 CAGR Period 16.0% 2019 - 2022 6.5% 2022 - 2026E U S $ Bi l l i o n Source: (1) China Veterinary Drug Association, Literature Review, and Frost & Sullivan
Slide 23: Industry Overview
Industry Overview Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis 23 Historical and Forecasted Market Size of Poultry Vaccine in China, 2019 - 2026E 0 . 56 0.92 1 . 24 1 . 20 1.27 1 . 33 1 . 39 1 . 45 2019 2020 2021 2022 2023E 2024E 2025E 2026E CAGR Period
Slide 24: Industry Overview
Industry Overview 0.20 0.25 0.30 0.29 0.33 0.36 0.38 0.39 2 0 1 9 2 0 2 0 2 0 2 1 2 0 2 2 2 0 2 3E 2 0 2 4E 2 0 2 5E 2 0 2 6E CAGR Period 13.2% 2019 - 2022 7.8% 2022 - 2026E US$ B i l l i on Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis 0.03 0.03 0.03 0.
Slide 25: Content
C o ntent Company and Business Overview 01 Industry Overview Growth Strategies Financial Highlights 02 03 04
Slide 26: Growth Strategies
Growth Strategies 26 01 02 03 04 05 Develop high - demand products and expand business by entering pet vaccines industry Expand sales and distribution network • Continue to increase sales to existing customers and focus on developing new markets and new customers • Entry into Southeast Asia market,
Slide 27: Content
C o ntent Company and Business Overview 01 Industry Overview Growth Strategies Financial Highlights 02 03 04
Slide 28: Financial Highlights
Financial Highlights $2 9.8 F Y 2 0 22 F Y 2 0 23 Revenue US$ Million $36.7 90 . 5% 6 . 3% 3 . 2% Revenue Breakdown by Products 89.3% 7 . 3% 3 . 4% FY2022 FY2023 28 Swine vaccines See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achiev
Slide 29: Financial Highlights
Financial Highlights Net Income $21.6 $1 8.3 FY2022 FY2 0 23 Gross Profit and Gross Profit Margin US$ Million Gross profit margin 61.4% 59.0% 29 $7 .8 See offering documents for further risks and disclosures. There is no guarantee that any specific outcome will be achieved. Investments may be specul
Slide 30: Contact
C o ntact 30 Issue r : Email: ir@jlzybio.com Tel: +86 - 0432 - 63047008 Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China Zhengye Biotechnology Holding Limited Underwriter: Email: info@kingswoodus.com Tel: +1 - 800 - 535 - 6981 Address: Tower
Zhengye Biotechnology Holding — IPO Roadshow (August 2024) on 6ix